You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
智飛生物和康希諾AH股齊步拉昇 入選中國新冠疫苗加強針“混打”方案
格隆匯 02-18 14:55
格隆匯2月18日丨智飛生物(300122.SZ)盤中一度拉昇漲超4%,康希諾A一度拉昇漲超6%,H股拉昇漲超7%。有媒體稱新冠疫苗加強針“混打”方案或即將出台。現階段可在全程接種國藥中生北京、科興中維、中生武漢的新冠病毒滅活疫苗滿6個月,且未完成同源加強免疫的18歲及以上人羣中實施序貫加強免疫接種,目標人羣可選擇智飛龍科馬公司的重組蛋白疫苗或天津康希諾公司的腺病毒載體疫苗中的一種,免費開展1劑次序貫加強針。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account